Welcome to our dedicated page for Livanova Plc news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on Livanova Plc stock.
LivaNova PLC (NASDAQ: LIVN) is a global medical technology company headquartered in London, focused on select neurological and cardiac conditions. This news page aggregates company announcements, clinical updates, investor communications, and other disclosures that LivaNova issues through press releases and related channels.
Readers can find coverage of LivaNova’s neuromodulation activities, including developments in VNS Therapy for Drug‑Resistant Epilepsy and results from the CORE‑VNS real‑world study. News items also describe health economics analyses, reimbursement decisions affecting VNS Therapy procedures under U.S. Medicare programs, and scientific presentations at major epilepsy meetings.
The feed also includes updates on LivaNova’s cardiopulmonary business and its heart‑lung support technologies, as well as information on its work in obstructive sleep apnea through proximal hypoglossal nerve stimulation and the aura6000 investigational system. Articles may highlight data from randomized controlled trials, long‑term follow‑up analyses, and presentations at specialized surgical sleep and medical conferences.
In addition, investors can follow LivaNova’s participation in healthcare investment conferences, Investor Day events, and quarterly financial result announcements, which the company often distributes via press release and webcasts. By reviewing this page, users can track how LivaNova communicates about its core Epilepsy and Cardiopulmonary businesses, its research programs, and its long‑range strategic plans.
For anyone researching LIVN stock or monitoring developments in medical technology for neurological and cardiac conditions, this news page offers a centralized view of LivaNova’s public announcements over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
LivaNova PLC (Nasdaq: LIVN) announced the resignation of CEO Damien McDonald, effective immediately. William A. Kozy, Chair of the Board, will serve as interim CEO while the company searches for a permanent replacement. Kozy brings significant experience from his career at Becton Dickinson and as Vice Chair at The Cooper Companies. The company also reported preliminary Q1 2023 revenue of $263 million, marking a 9% increase compared to $240 million in Q1 2022. LivaNova is committed to maintaining its focus on growth and innovation during this transition, with full results set to be released on May 3, 2023.
LivaNova PLC (Nasdaq: LIVN) will host a conference call to discuss its first-quarter 2023 results on May 3, 2023, at 1 p.m. London time (8 a.m. Eastern Time). The results will be released prior to the call, and a live audiocast will be accessible on the company's website. Investors can join by dialing the respective numbers for the U.S. and international callers. The company has nearly five decades of experience in the medical technology sector and operates in over 100 countries. A replay of the call will be available on their website for 90 days.
LivaNova PLC (NASDAQ: LIVN) has received FDA 510(k) clearance for its Essenz™ Heart-Lung Machine (HLM), marking the start of its commercial launch in the U.S. The company also secured approvals from Health Canada and the Japanese PMDA, initiating a broader commercial release in Europe. The Essenz Perfusion System enhances clinical workflows and patient care during cardiopulmonary bypass (CPB) procedures, featuring reliable technology based on the LivaNova S5™ HLM. Key benefits include individualized patient care, user-friendly interfaces, and robust support worldwide.